Comparison of the D1 dopamine full agonists, dihydrexidine and doxanthrine, in the 6-OHDA rat model of Parkinson's disease

[1] Asin KE(1993)Effects of repeated dopamine D1 receptor stimulation on rotation and c-fos expression Eur J Pharmacol 235 167-168

[2] Wirtshafter D(2006)Dopamine agonists in the treatment of Parkinson's disease Expert Rev Neurother 6 81-89

[3] Bonuccelli U(1987)Selective D-1 dopamine receptor agonist treatment of Parkinson's disease J Neural Transm 68 41-50

[4] Pavese N(1990)Trans-10,11-dihydroxy-5,6,6a,7,8,12b-hexahydrobenzo[a]phenanthridine: a highly potent selective dopamine D1 full agonist J Med Chem 33 1756-1764

[5] Braun A(1999)Effects of alpha-2 adrenoceptor agonists and antagonists on circling behavior in rats with unilateral 6-hydroxydopamine lesions of the nigrostriatal pathway J Pharmacol Exp Ther 288 798-804

[6] Fabbrini G(2006)trans-2,3-dihydroxy-6a,7,8,12b-tetrahydro-6H-chromeno[3,4-c]isoquinoline: synthesis, resolution, and preliminary pharmacological characterization of a new dopamine D1 receptor full agonist J Med Chem 49 6848-6857

[7] Mouradian MM(2002)Modeling Parkinson's disease in rats: an evaluation of 6-OHDA lesions of the nigrostriatal pathway Exp Neurol 175 303-317

[8] Serrati C(2004)Levodopa and the progression of Parkinson's disease N Engl J Med 351 2498-2508

[9] Barone P(2002)The heterogeneity of idiopathic Parkinson's disease J Neurol 249 138-145

[10] Chase TN(2011)Therapies for dopaminergic-induced dyskinesias in Parkinson disease Ann Neurol 69 919-927

[1] Asin KE(1993)Effects of repeated dopamine D1 receptor stimulation on rotation and c-fos expression Eur J Pharmacol 235 167-168

[2] Wirtshafter D(2006)Dopamine agonists in the treatment of Parkinson's disease Expert Rev Neurother 6 81-89

[3] Bonuccelli U(1987)Selective D-1 dopamine receptor agonist treatment of Parkinson's disease J Neural Transm 68 41-50

[4] Pavese N(1990)Trans-10,11-dihydroxy-5,6,6a,7,8,12b-hexahydrobenzo[a]phenanthridine: a highly potent selective dopamine D1 full agonist J Med Chem 33 1756-1764

[5] Braun A(1999)Effects of alpha-2 adrenoceptor agonists and antagonists on circling behavior in rats with unilateral 6-hydroxydopamine lesions of the nigrostriatal pathway J Pharmacol Exp Ther 288 798-804

[6] Fabbrini G(2006)trans-2,3-dihydroxy-6a,7,8,12b-tetrahydro-6H-chromeno[3,4-c]isoquinoline: synthesis, resolution, and preliminary pharmacological characterization of a new dopamine D1 receptor full agonist J Med Chem 49 6848-6857

[7] Mouradian MM(2002)Modeling Parkinson's disease in rats: an evaluation of 6-OHDA lesions of the nigrostriatal pathway Exp Neurol 175 303-317

[8] Serrati C(2004)Levodopa and the progression of Parkinson's disease N Engl J Med 351 2498-2508

[9] Barone P(2002)The heterogeneity of idiopathic Parkinson's disease J Neurol 249 138-145

[10] Chase TN(2011)Therapies for dopaminergic-induced dyskinesias in Parkinson disease Ann Neurol 69 919-927